Fort L.P. raised its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 36.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,454 shares of the medical research company’s stock after buying an additional 5,243 shares during the period. Iqvia comprises 0.6% of Fort L.P.’s portfolio, making the stock its 19th largest holding. Fort L.P.’s holdings in Iqvia were worth $2,798,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Mitsubishi UFJ Securities Holdings Co. Ltd. purchased a new stake in shares of Iqvia in the first quarter worth $94,000. Blackcrane Capital LLC increased its stake in shares of Iqvia by 28.1% in the first quarter. Blackcrane Capital LLC now owns 51,005 shares of the medical research company’s stock worth $7,337,000 after purchasing an additional 11,183 shares in the last quarter. GYL Financial Synergies LLC purchased a new stake in shares of Iqvia in the first quarter worth $4,349,000. Riverhead Capital Management LLC increased its stake in shares of Iqvia by 19.2% in the first quarter. Riverhead Capital Management LLC now owns 7,521 shares of the medical research company’s stock worth $1,082,000 after purchasing an additional 1,211 shares in the last quarter. Finally, Northeast Financial Consultants Inc bought a new position in shares of Iqvia during the first quarter worth $642,000. 89.78% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts recently weighed in on the stock. Svb Leerink assumed coverage on shares of Iqvia in a research report on Tuesday, May 28th. They set an “outperform” rating and a $160.00 target price for the company. Leerink Swann assumed coverage on shares of Iqvia in a research report on Tuesday, May 28th. They set an “outperform” rating and a $136.38 target price for the company. Zacks Investment Research upgraded shares of Iqvia from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. TheStreet lowered shares of Iqvia from a “b” rating to a “c+” rating in a research report on Wednesday, May 1st. Finally, Wolfe Research assumed coverage on shares of Iqvia in a research report on Tuesday, April 2nd. They set a “market perform” rating for the company. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $147.02.
IQV stock opened at $141.08 on Friday. Iqvia Holdings Inc has a 52 week low of $97.64 and a 52 week high of $146.10. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.14 and a quick ratio of 1.14. The firm has a market cap of $27.59 billion, a price-to-earnings ratio of 27.55, a price-to-earnings-growth ratio of 1.70 and a beta of 0.77.
Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.12. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The business had revenue of $2.68 billion during the quarter, compared to analyst estimates of $2.67 billion. During the same quarter last year, the business earned $1.34 earnings per share. Iqvia’s quarterly revenue was up 4.7% compared to the same quarter last year. Research analysts anticipate that Iqvia Holdings Inc will post 5.88 EPS for the current fiscal year.
In other Iqvia news, insider Kevin C. Knightly sold 46,080 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $138.06, for a total transaction of $6,361,804.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ari Bousbib sold 96,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $140.96, for a total transaction of $13,532,160.00. The disclosure for this sale can be found here. Insiders have sold 143,273 shares of company stock valued at $20,066,890 in the last quarter. 6.00% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Fort L.P. Increases Holdings in Iqvia Holdings Inc (NYSE:IQV)” was originally posted by Riverton Roll and is the property of of Riverton Roll. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://rivertonroll.com/news/2019/06/14/fort-l-p-increases-holdings-in-iqvia-holdings-inc-nyseiqv.html.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading: How do CD ladders protect against rising interest rates?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.